A network-guided approach for unraveling potential phar-ma-cological role of JAK2 and analysis of the frequency the mutations in myeloproliferative neoplasm Saudi Patients

JAK2 is a non-receptor tyrosine kinase that regulates cellular proliferation and growth. JAK2 is frequently the target of mutations in cancer, particularly in myeloid leukemia, lymphoid leukemia, and myeloproliferative neoplasms (MPN), because of its important function in hematopoiesis. There is a lot of work being done to discover therapeutic medications for the affected people because these mutations are widespread among various ethnicities throughout the world. Constitutive kinase activation is the most frequent outcome of JAK2 mutations, whether they are point, deletion, or gene fusion mutations. A drug’s mechanism of action can frequently be divided into positive (activator, potentiator, agonist, etc.) and negative (inhibitor, blocker, antagonist, etc.) categories. The combined mechanisms of action of various medications on the group of shared targets can be examined using the signed edges of a drug-target network. Herein, our objective was to identify the mutations detected in a previous study by whole genome sequencing using the Mis-eq Illumina Platform. Also, it will help us to find the availability and the frequency of JAK2, CARL and MPL mutations in Saudi CML and MPN patients. Finally, we applied a network-guided approach to predict potential herbal drugs for JAK2. Based on our results, we conclude that JAK2 has significant mutation in in case of MPN and Allicin, Curcumin, and Gingerol could be the potential herbal drugs against targeting MPN.